NZ758360A - Btla agonist antibodies and uses thereof - Google Patents

Btla agonist antibodies and uses thereof

Info

Publication number
NZ758360A
NZ758360A NZ758360A NZ75836018A NZ758360A NZ 758360 A NZ758360 A NZ 758360A NZ 758360 A NZ758360 A NZ 758360A NZ 75836018 A NZ75836018 A NZ 75836018A NZ 758360 A NZ758360 A NZ 758360A
Authority
NZ
New Zealand
Prior art keywords
agonist antibodies
btla agonist
antibodies
btla
agents
Prior art date
Application number
NZ758360A
Other languages
English (en)
Inventor
Andrew Charles Vendel
Shane Krummen Atwell
Victor H Obungu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ758360A publication Critical patent/NZ758360A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ758360A 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof NZ758360A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ758360A true NZ758360A (en) 2022-10-28

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ758360A NZ758360A (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Country Status (26)

Country Link
US (2) US10604573B2 (enExample)
EP (1) EP3625257A1 (enExample)
JP (2) JP6790304B2 (enExample)
KR (3) KR102294051B1 (enExample)
CN (3) CN110621699B (enExample)
AR (1) AR111752A1 (enExample)
AU (2) AU2018269585B2 (enExample)
BR (1) BR112019021547A2 (enExample)
CA (2) CA3184628A1 (enExample)
CL (1) CL2019003215A1 (enExample)
CO (1) CO2019012756A2 (enExample)
CR (1) CR20190521A (enExample)
DO (1) DOP2019000293A (enExample)
EA (1) EA201992460A1 (enExample)
EC (1) ECSP19082184A (enExample)
JO (1) JOP20190261A1 (enExample)
MA (1) MA49133A (enExample)
MX (1) MX381033B (enExample)
MY (2) MY197425A (enExample)
NZ (1) NZ758360A (enExample)
PE (1) PE20191843A1 (enExample)
PH (1) PH12019502575A1 (enExample)
SA (1) SA519410534B1 (enExample)
TW (4) TWI804044B (enExample)
WO (1) WO2018213113A1 (enExample)
ZA (1) ZA201906954B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
IL302135A (en) * 2020-10-23 2023-06-01 Anaptysbio Inc B and t lymphocyte attenuator (btla) modulators and method of using same
MX2024009326A (es) * 2022-01-29 2024-08-06 Hifibio Inc Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2669921A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
EP2459594A1 (en) * 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
JP2018521959A (ja) * 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP7227007B2 (ja) * 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体

Also Published As

Publication number Publication date
JOP20190261A1 (ar) 2019-11-05
TW201946932A (zh) 2019-12-16
JP2021019642A (ja) 2021-02-18
KR20210106033A (ko) 2021-08-27
AU2018269585B2 (en) 2021-09-02
US20200239578A1 (en) 2020-07-30
AU2018269585A1 (en) 2019-10-31
CN110621699A (zh) 2019-12-27
TWI747043B (zh) 2021-11-21
KR102294051B1 (ko) 2021-08-27
CA3184628A1 (en) 2018-11-22
CL2019003215A1 (es) 2020-04-13
US20180334502A1 (en) 2018-11-22
TW202334237A (zh) 2023-09-01
JP2020518288A (ja) 2020-06-25
MY198277A (en) 2023-08-18
CO2019012756A2 (es) 2020-01-17
KR20220158847A (ko) 2022-12-01
CN117402245A (zh) 2024-01-16
TW201904991A (zh) 2019-02-01
PE20191843A1 (es) 2019-12-31
ZA201906954B (en) 2021-06-30
MY197425A (en) 2023-06-16
MX2019013604A (es) 2019-12-18
MA49133A (fr) 2020-03-25
DOP2019000293A (es) 2019-12-15
CN110621699B (zh) 2023-10-31
EA201992460A1 (ru) 2020-03-18
SA519410534B1 (ar) 2023-11-08
TWI804044B (zh) 2023-06-01
AR111752A1 (es) 2019-08-14
JP6790304B2 (ja) 2020-11-25
ECSP19082184A (es) 2019-11-30
PH12019502575A1 (en) 2020-07-13
BR112019021547A2 (pt) 2020-05-12
KR20190140969A (ko) 2019-12-20
TW202233681A (zh) 2022-09-01
US11396545B2 (en) 2022-07-26
US10604573B2 (en) 2020-03-31
JP7072622B2 (ja) 2022-05-20
CN117402244A (zh) 2024-01-16
CR20190521A (es) 2020-01-06
TWI677504B (zh) 2019-11-21
CA3064518A1 (en) 2018-11-22
MX381033B (es) 2025-03-12
EP3625257A1 (en) 2020-03-25
WO2018213113A1 (en) 2018-11-22
AU2021277743A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
PH12019502575A1 (en) Btla agonist antibodies and uses thereof
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
CL2018000729A1 (es) Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso.
MX2020012562A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12017501748B1 (en) Antibodies to icos
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
EP3954713A3 (en) Bispecific antibodies that bind to cd38 and cd3
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
IL276746A (en) Kir3dl3 as hhla2 receptor, anti-hhla2 antibodies and their uses
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
MX2016013241A (es) Animales no humanos que tienen receptores fc gamma humanizados.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: REPLACEMENT SPECIFICATION AND CLAIMS FOR EXAMINATION; FILING DATE: 18 OCT 2019; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 25 OCT 2019; TITLE: BTLA AGONIST ANTIBODIES AND USES THEREOF; FILING DATE: 28 NOV 2021; STATUS: PROPOSED; KIND CODE:

Effective date: 20211209

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2024 BY ANAQUA SERVICES

Effective date: 20230420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2025 BY ANAQUA SERVICES

Effective date: 20240418

LAPS Patent lapsed